[144] UNITED THERAPEUTICS Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics (UTHR) Form 144 shows a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,803,449.20 and an approximate sale date of 10/08/2025. The filing reports the shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement and notes 294,000 shares were acquired at that time via exercised options paid with common shares.

The notice lists numerous sales by Martine Rothblatt during 09/09/2025–10/07/2025, typically in blocks of 4,000 shares per transaction, with gross proceeds shown for each date. The filing states the seller represents no undisclosed material adverse information about the issuer.

Positive

• Securities were acquired under an executive deferred compensation plan on 03/15/2016
• Filer provides seller's certification of no undisclosed material adverse information

Negative

• Repeated insider sales across 09/09/2025–10/07/2025
• Multiple daily blocks of 4,000 shares sold could be interpreted as systematic disposition

Insights

Insider Transactions Analyst

TL;DR: Regular small-block insider sales were reported across September–October 2025; proposed sale is another similar block.

The filing records a proposed sale of 4,000 shares valued at $1,803,449.20 on 10/08/2025, and shows multiple prior sales by the same person between 09/09/2025 and 10/07/2025, mostly in 4,000-share increments with documented gross proceeds. This pattern indicates systematic dispositions rather than a single large divestment.

Key dependencies include the continued presence of identical daily block sizes and the stated acquisition source (executive deferred compensation on 03/15/2016). Watch for any additional filings that disclose changes in frequency, block size, or cumulative amounts within the next 30 days.

Corporate Governance Specialist

TL;DR: The seller affirms no undisclosed material adverse information and documents the original acquisition method.

The notice includes the seller's representation that they do not possess undisclosed material adverse information and documents the shares were acquired via exercised options under an executive deferred compensation arrangement on 03/15/2016 (amount 294,000 shares). That provenance aligns with routine, non-arms-length compensation-origin dispositions.

Risks stem from potential market interpretation of frequent insider sales; investors may monitor whether sales continue or accelerate and whether any supplementary disclosures are filed within the next few weeks.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20th Floor NEW YORK NY 10017	4000	1803449.20	45230000	10/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672592.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736488.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723739.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/26/2025	4000	1712891.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/29/2025	4000	1702526.76
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/30/2025	4000	1691357.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/01/2025	4000	1701796.53
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/02/2025	4000	1739525.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/03/2025	4000	1784847.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/06/2025	4000	1798765.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/07/2025	4000	1807320.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for UTHR report?

The Form 144 reports a proposed sale of 4,000 common shares with an aggregate market value of $1,803,449.20 and an approximate sale date of 10/08/2025.

Who is the seller listed on the UTHR Form 144?

The seller identified is Martine Rothblatt, with multiple sales recorded between 09/09/2025 and 10/07/2025.

How were the shares being sold originally acquired?

The shares were acquired on 03/15/2016 under an executive deferred compensation arrangement; the filing lists 294,000 shares acquired via exercised options.

Which broker is handling the proposed sale?

The proposed sale is through TD Securities (USA) LLC located at 125 Park Ave, New York, NY.

What is the number of shares outstanding used in the filing?

The filing lists 45,230,000 shares outstanding.